SE0104341D0 - New use - Google Patents

New use

Info

Publication number
SE0104341D0
SE0104341D0 SE0104341A SE0104341A SE0104341D0 SE 0104341 D0 SE0104341 D0 SE 0104341D0 SE 0104341 A SE0104341 A SE 0104341A SE 0104341 A SE0104341 A SE 0104341A SE 0104341 D0 SE0104341 D0 SE 0104341D0
Authority
SE
Sweden
Prior art keywords
alzheimer
disease
prevention
formula
treatment
Prior art date
Application number
SE0104341A
Other languages
English (en)
Inventor
Stefan Berg
Ratan Bhat
Sven Hellberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0104341A priority Critical patent/SE0104341D0/sv
Publication of SE0104341D0 publication Critical patent/SE0104341D0/sv
Priority to DE60223841T priority patent/DE60223841T2/de
Priority to PCT/SE2002/002372 priority patent/WO2003053444A1/en
Priority to AU2002359163A priority patent/AU2002359163A1/en
Priority to EP02793677A priority patent/EP1458395B1/en
Priority to JP2003554201A priority patent/JP2005516948A/ja
Priority to ES02793677T priority patent/ES2295440T3/es
Priority to US10/499,685 priority patent/US20050075351A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
SE0104341A 2001-12-20 2001-12-20 New use SE0104341D0 (sv)

Priority Applications (8)

Application Number Priority Date Filing Date Title
SE0104341A SE0104341D0 (sv) 2001-12-20 2001-12-20 New use
DE60223841T DE60223841T2 (de) 2001-12-20 2002-12-18 Medizinische verwendung von gsk3-hemmenden oxindolderivaten
PCT/SE2002/002372 WO2003053444A1 (en) 2001-12-20 2002-12-18 New use
AU2002359163A AU2002359163A1 (en) 2001-12-20 2002-12-18 New use
EP02793677A EP1458395B1 (en) 2001-12-20 2002-12-18 Medical use of gsk3-inhibiting oxindole derivatives
JP2003554201A JP2005516948A (ja) 2001-12-20 2002-12-18 新規な使用
ES02793677T ES2295440T3 (es) 2001-12-20 2002-12-18 Uso medico de derivados de oxindol que inhiben gsk3.
US10/499,685 US20050075351A1 (en) 2001-12-20 2002-12-18 Use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0104341A SE0104341D0 (sv) 2001-12-20 2001-12-20 New use

Publications (1)

Publication Number Publication Date
SE0104341D0 true SE0104341D0 (sv) 2001-12-20

Family

ID=20286440

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0104341A SE0104341D0 (sv) 2001-12-20 2001-12-20 New use

Country Status (8)

Country Link
US (1) US20050075351A1 (sv)
EP (1) EP1458395B1 (sv)
JP (1) JP2005516948A (sv)
AU (1) AU2002359163A1 (sv)
DE (1) DE60223841T2 (sv)
ES (1) ES2295440T3 (sv)
SE (1) SE0104341D0 (sv)
WO (1) WO2003053444A1 (sv)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60221283T2 (de) 2001-12-21 2008-03-20 Astrazeneca Ab Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
SE0302546D0 (sv) * 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
SE527004C2 (sv) * 2003-11-26 2005-12-06 Kvaser Consultant Ab Anordning av distribuerat för simulering i distribuerade styrsystem t ex i fordon
SE528072C2 (sv) * 2004-01-16 2006-08-29 Kvaser Consultant Ab Anordning, enhet och arrangemang vid ett eller flera distribuerade system för insamling av drift eller felinformation
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
AR056968A1 (es) * 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
AR053713A1 (es) * 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
CA2643044A1 (en) * 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2076518A1 (en) * 2006-10-12 2009-07-08 Xenon Pharmaceuticals Inc. Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
AU2007307638A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-C] pyridine-3-3 ' -indol) -2' (1'H)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
EP2073806B1 (en) * 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
JP5406030B2 (ja) 2006-10-21 2014-02-05 アボット ゲーエムベーハー ウント カンパニー カーゲー 複素環化合物およびそれらのグリコーゲンシンターゼキナーゼ３阻害薬としての使用
US20090291982A1 (en) * 2008-05-22 2009-11-26 Astrazeneca Ab New Substituted Oxindole Derivative 352
US8101647B2 (en) * 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
CN102256983B (zh) 2008-10-17 2017-04-05 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
TW201040191A (en) * 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
CN102753556B (zh) 2009-10-14 2015-05-13 泽农医药公司 螺-羟吲哚化合物的合成方法
WO2011047173A2 (en) * 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
BR112012021086A2 (pt) 2010-02-26 2016-05-17 Xenon Pharmaceuticals Inc composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
EP2621914B1 (en) 2010-09-27 2016-12-28 Abbott GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
AU8816298A (en) * 1997-08-22 1999-03-16 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
EP1105376B1 (en) * 1998-08-20 2005-02-09 Sumitomo Pharmaceuticals Company, Limited Oxindole derivatives as growth hormone releasers
EP1136493A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-(Thienopyridinyl)pyrimidone, 2-(furopyridinyl)pyrimidone 2-(isoquinolinyl)pyrimidone, 2-(pyridoindolyl)pyrimidone and 2-(benzofuropyridinyl)pyrimidone derivatives

Also Published As

Publication number Publication date
DE60223841D1 (de) 2008-01-10
DE60223841T2 (de) 2008-10-09
EP1458395A1 (en) 2004-09-22
EP1458395B1 (en) 2007-11-28
ES2295440T3 (es) 2008-04-16
WO2003053444A1 (en) 2003-07-03
AU2002359163A1 (en) 2003-07-09
US20050075351A1 (en) 2005-04-07
JP2005516948A (ja) 2005-06-09

Similar Documents

Publication Publication Date Title
SE0104341D0 (sv) New use
WO2003053330A3 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer’s disease and conditions associated with glycogen synthase kinase-3
UY27592A1 (es) Nuevo uso
ATE407928T1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
JO2282B1 (en) Oxazole derivatives
TW200621762A (en) Novel compounds
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
DK1689721T3 (da) Aminopyrazolderivater som GSK-3-ihibitorer
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
ES2193875A1 (es) Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
ATE386725T1 (de) Heterocyclylverbindungen
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
BR0309185A (pt) Medicamento contendo beta-miméticos e um novo anticolinérgico
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
DK1641454T3 (da) Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
HUP0402577A2 (hu) Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra
MY133527A (en) Isoquinoline derivatives
SE0102440D0 (sv) New compound
IL150817A0 (en) Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases